Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
The promise seen in Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, should offset payer and HTA reluctance to use the monoclonal antibody despite its conditional EU marketing approval status.
You may also be interested in...
News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.
It looks like the end for Latruvo after a late-stage trial in soft tissue sarcoma patients did not confirm the overall survival benefit seen in the Phase II study that saw the Lilly drug get a speedy approval from the FDA and the EMA in 2016.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.